Hisamitsu Pharmaceutical Co Inc
TSE:4530

Watchlist Manager
Hisamitsu Pharmaceutical Co Inc Logo
Hisamitsu Pharmaceutical Co Inc
TSE:4530
Watchlist
Price: 5 200 JPY 15.56% Market Closed
Market Cap: 390.8B JPY

Relative Value

The Relative Value of one Hisamitsu Pharmaceutical Co Inc stock under the Base Case scenario is 3 594.16 JPY. Compared to the current market price of 5 200 JPY, Hisamitsu Pharmaceutical Co Inc is Overvalued by 31%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
3 594.16 JPY
Overvaluation 31%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
68
vs Industry
51
Median 3Y
2.1
Median 5Y
2.3
Industry
2.6
Forward
2.3
vs History
80
vs Industry
25
Median 3Y
20.3
Median 5Y
24.3
Industry
21.4
Forward
17.5
vs History
50
vs Industry
27
Median 3Y
17.7
Median 5Y
20.1
Industry
16.4
vs History
61
vs Industry
0
Median 3Y
58
Median 5Y
46.8
Industry
22.8
vs History
33
vs Industry
57
Median 3Y
1.1
Median 5Y
1.2
Industry
2.2
vs History
38
vs Industry
66
Median 3Y
1.2
Median 5Y
1.2
Industry
2.9
Forward
1.6
vs History
39
vs Industry
69
Median 3Y
2.2
Median 5Y
2.2
Industry
5.5
vs History
77
vs Industry
33
Median 3Y
9.4
Median 5Y
10.1
Industry
13
Forward
10.3
vs History
77
vs Industry
30
Median 3Y
12.9
Median 5Y
14.5
Industry
16.5
vs History
30
vs Industry
38
Median 3Y
11.2
Median 5Y
11.2
Industry
15.6
vs History
57
vs Industry
0
Median 3Y
33.6
Median 5Y
32.5
Industry
18.7
vs History
34
vs Industry
60
Median 3Y
0.9
Median 5Y
1
Industry
1.9

Multiples Across Competitors

Competitors Multiples
Hisamitsu Pharmaceutical Co Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
Hisamitsu Pharmaceutical Co Inc
TSE:4530
369.8B JPY 2.4 18.8 10.4 14.3
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.7 36.7 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
492.8B USD 5.3 19.6 16.1 20.8
CH
Roche Holding AG
SIX:ROG
262.7B CHF 4.3 27.9 11.9 13.9
UK
AstraZeneca PLC
LSE:AZN
217.7B GBP 5.1 31.3 108.6 158.9
CH
Novartis AG
SIX:NOVN
214B CHF 4.8 18.7 11.8 15.3
US
Merck & Co Inc
NYSE:MRK
270.8B USD 4.2 14.2 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.1 15.6 10.8 12.6
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.6B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
JP
Hisamitsu Pharmaceutical Co Inc
TSE:4530
Average P/E: 23.9
18.8
-5%
N/A
US
Eli Lilly and Co
NYSE:LLY
54.7
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.9
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.3
37%
0.8
CH
Novartis AG
SIX:NOVN
18.7
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.6
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
JP
Hisamitsu Pharmaceutical Co Inc
TSE:4530
Average EV/EBITDA: 400.8
10.4
-1%
N/A
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.9
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.6
10%
10.9
CH
Novartis AG
SIX:NOVN
11.8
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
JP
Hisamitsu Pharmaceutical Co Inc
TSE:4530
Average EV/EBIT: 1 713.5
14.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.9
23%
6.9
CH
Novartis AG
SIX:NOVN
15.3
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.6
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5